BCL2L12

Across TCGA pan-cancer cohorts, BCL2L12 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of BCL2L12’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BCL2L12 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BCL2L12 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

HNSC, LUAD, and CCRCC are the cancer types where BCL2L12 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL2L12 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.283	.014	8	view →
LUAD	Female	All	−0.496	.001	5	view →
CCRCC	All	All	+0.360	.032	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

BCL2L12–HNSC

Open the HNSC breakdown →